AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov W, Mita M, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin E, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. Npj Precision Oncology 2023, 7: 18. PMID: 36797347, PMCID: PMC9935518, DOI: 10.1038/s41698-023-00360-5.Peer-Reviewed Original ResearchEndocrine therapyProgressive diseaseCDK4/6 inhibitionImmune cellsTumor epitheliumOpen-label multicenter clinical trialMetastatic breast cancer patientsPI3K/AKT/mTOR activationFirst-line treatmentMetastatic breast cancerBreast cancer patientsAkt/mTOR activationMulticenter clinical trialAkt/mTORMBC patientsCancer patientsPredictive markerClinical trialsDisease progressionBreast cancerTreatment selectionTissue biopsiesPatientsNumber of FDAMTOR activation